Open AccessCemiplimab (REGN2810), a Fully Human Anti-PD-1 Monoclonal Antibody, for Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: Initial Safety and Efficacy from Expansion Cohorts of Phase 1 Study
Author(s) -
Kyriakos P. Papadopoulos,
Taofeek K. Owonikoko,
Melissa L. Johnson,
Irene Braña,
Marta Gil-Martín,
Raymond P. Perez,
Víctor Moreno,
April K.S. Salama,
Emiliano Calvo,
Nelson S. Yee,
Howard Safran,
Antonio González-Martín,
Raid Aljumaily,
Daruka Mahadevan,
Kosalai Kal Mohan,
Jingjin Li,
Elizabeth Stankevich,
Israel Lowy,
Matthew G. Fury,
Jade Homsi
Publication year - 2018
Publication title -
skin
Language(s) - English
Resource type - Journals
ISSN - 2574-1624
DOI - 10.25251/skin.2.supp.45
Subject(s) - medicine , monoclonal antibody , oncology , basal cell , monoclonal , antibody , immunology
not available. Disclosures: Study sponsored by Regeneron Pharmaceuticals Inc. and Sanofi. Copyright 2018 SKIN